QuidelOrtho (NASDAQ:QDEL) Shares Down 6.5% – Time to Sell?

QuidelOrtho Corporation (NASDAQ:QDEL) shares dropped 6.5% during trading on Tuesday . The company traded as low as $17.03 and last traded at $17.05. Approximately 125,249 shares changed hands during mid-day trading, a decline of 93% from the average session volume of 1,860,770 shares. The stock had previously closed at $18.23.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the company. UBS Group reissued a “neutral” rating and set a $12.00 price objective on shares of QuidelOrtho in a report on Thursday, May 7th. Weiss Ratings reissued a “sell (e+)” rating on shares of QuidelOrtho in a research note on Tuesday, April 21st. Jefferies Financial Group restated a “hold” rating on shares of QuidelOrtho in a report on Monday. Wall Street Zen raised QuidelOrtho from a “sell” rating to a “hold” rating in a research note on Sunday. Finally, Zacks Research upgraded shares of QuidelOrtho from a “strong sell” rating to a “hold” rating in a report on Monday, June 15th. Four investment analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Reduce” and an average price target of $14.88.

QuidelOrtho Stock Down 3.6%

The firm has a market capitalization of $1.20 billion, a price-to-earnings ratio of -0.99 and a beta of 0.77. The stock has a fifty day moving average of $12.61 and a two-hundred day moving average of $20.19. The company has a debt-to-equity ratio of 1.33, a current ratio of 1.43 and a quick ratio of 0.80.

QuidelOrtho (NASDAQ:QDEL) last announced its earnings results on Tuesday, May 5th. The company reported ($0.04) EPS for the quarter, missing the consensus estimate of $0.37 by ($0.41). QuidelOrtho had a positive return on equity of 4.25% and a negative net margin of 45.57%.The company had revenue of $619.80 million for the quarter, compared to analyst estimates of $665.23 million. During the same period in the previous year, the firm posted $0.74 earnings per share. The firm’s quarterly revenue was down 10.5% compared to the same quarter last year. QuidelOrtho has set its FY 2026 guidance at 1.800-2.000 EPS. Sell-side analysts anticipate that QuidelOrtho Corporation will post 1.83 earnings per share for the current year.

Institutional Trading of QuidelOrtho

Several institutional investors have recently added to or reduced their stakes in QDEL. Hantz Financial Services Inc. grew its position in QuidelOrtho by 50.3% during the fourth quarter. Hantz Financial Services Inc. now owns 1,082 shares of the company’s stock worth $31,000 after buying an additional 362 shares in the last quarter. ProShare Advisors LLC raised its holdings in shares of QuidelOrtho by 3.0% in the 4th quarter. ProShare Advisors LLC now owns 13,164 shares of the company’s stock valued at $376,000 after acquiring an additional 388 shares in the last quarter. State of Alaska Department of Revenue raised its holdings in shares of QuidelOrtho by 1.1% in the 4th quarter. State of Alaska Department of Revenue now owns 38,333 shares of the company’s stock valued at $1,093,000 after acquiring an additional 424 shares in the last quarter. Moody National Bank Trust Division boosted its position in shares of QuidelOrtho by 1.0% during the 4th quarter. Moody National Bank Trust Division now owns 51,512 shares of the company’s stock valued at $1,471,000 after acquiring an additional 526 shares during the last quarter. Finally, California State Teachers Retirement System boosted its position in shares of QuidelOrtho by 1.2% during the 2nd quarter. California State Teachers Retirement System now owns 62,188 shares of the company’s stock valued at $1,792,000 after acquiring an additional 725 shares during the last quarter. 99.00% of the stock is currently owned by institutional investors.

QuidelOrtho Company Profile

QuidelOrtho is a global diagnostics company formed through the merger of Quidel Corporation and Ortho Clinical Diagnostics. The combined entity develops, manufactures and markets a broad portfolio of rapid and high-throughput diagnostic solutions across immunoassay, molecular diagnostics and transfusion medicine. Its offerings span point-of-care platforms for acute care testing as well as large-scale automated systems designed for clinical laboratories and blood banks.

The company’s product range includes rapid antigen and antibody tests for infectious diseases, molecular assays utilizing nucleic acid amplification technology, and integrated immunodiagnostic analyzers.